Navigation Links
Scientists unravel resistance to breast cancer treatment
Date:10/31/2012

Scientists have identified a molecular 'flag' in women with breast cancer who do not respond or have become resistant to the hormone drug tamoxifen.

Tamoxifen used alongside traditional chemotherapy and radiotherapy blocks the female hormone oestrogen that, in certain breast cancers, is required by the tumour to grow; it has been shown to improve cancer survival rates by up to one third.

However, about one third of patients with the appropriate type of breast cancer known as oestrogen receptor positive breast cancer do not respond to tamoxifen or develop resistance to the drug. Oestrogen receptor positive breast cancer is the most common form of the disease accounting for 70% of cases.

Now, a team from the University of Manchester's Paterson Institute for Cancer Research has identified a molecular flag or biomarker that will help doctors predict which patients will respond best to complementary (adjuvant) hormone therapy with tamoxifen.

"The identification of molecular flags to classify subgroups of breast cancer and so determine the best treatment for each patient is of increasing importance in cancer therapy," said study lead Professor Gran Landberg.

"Tamoxifen has been shown to be highly effective in some breast cancer patients when used alongside traditional cancer therapies but, in a third of cases, the result has not been what we would hope. If we can predict which patients will respond to tamoxifen, and those who won't, then this is clearly advantageous as it means the correct treatment is provided instantly which will improve disease outcomes."

The research, funded by the charity Breakthrough Breast Cancer and published in the journal PLoS One, looked at the connective tissue surrounding the tumour, which is known to send signals that help the cancer to grow. The team, part of the Manchester Cancer Research Centre, found that fibroblast cells the cells that make up connective tissue in our bodies differ in their characteristics from patient to patient and can give clues about tamoxifen treatment response

Co-author Dr Susann Busch said: "We analysed tissue samples from 564 women with invasive breast cancer, some of whom were given tamoxifen and some who weren't; this allowed us to make a comparison between treatment responses.

"We discovered that women who had low levels of a protein known as pERK in their cancer-associated fibroblasts did not respond to tamoxifen. Testing patients for the pERK flag could help doctors determine whether tamoxifen is an appropriate treatment for their patient or whether alternative therapies should be explored, so saving time and money."

The researchers now plan to further study molecular flags that are characteristic for cancer-associated fibroblasts. Understanding how fibroblasts help the tumour to grow will allow the development of new strategies to block their harmful signals and overcome drug resistance.


'/>"/>

Contact: Aeron Haworth
aeron.haworth@manchester.ac.uk
44-161-275-8383
University of Manchester
Source:Eurekalert

Related biology news :

1. Stanford scientists build the first all-carbon solar cell
2. Gladstone, Stanford scientists block toxic protein that plays key role in Lou Gehrigs disease
3. Scientists deepen genetic understanding of MS
4. Whitehead scientists identify major flaw in standard approach to global gene expression analysis
5. USDA scientists collaborate with global researchers to advance the mapping of the barley genome
6. Scientists uncover mechanism by which plants inherit epigenetic modifications
7. CT scan and 3-D print help scientists reconstruct an ancient mollusk
8. Scientists conclude high fructose corn syrup should not be blamed for obesity
9. Maintaining Earths sustainability: Scientists, engineers, educators take coordinated approach
10. UMN scientists get federal grant for biotechnology development to purify fracking water
11. Scientists reveal how natural antibiotic kills tuberculosis bacterium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 23, 2017 Research and Markets has announced ... & Trends - Industry Forecast to 2025" report to their ... The ... CAGR of around 8.8% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
(Date:3/22/2017)... 21, 2017 Vigilant Solutions , a ... enforcement agencies, announced today the appointment of retired FBI ... public safety business development. Mr. Sheridan brings ... including a focus on the aviation transportation sector, to ... position, Mr. Sheridan served as the Aviation Liaison Agent ...
(Date:3/16/2017)... , March 16, 2017 CeBIT 2017 - Against identity fraud with ... Reading ... Used combined in one project, multi-biometric solutions provide a crucial ... Used combined in ... ...
Breaking Biology News(10 mins):
(Date:3/29/2017)... 2017 WuXi Biologics, a leading open-access ... biologics and a WuXi AppTec Affiliate, today announced ... Bioprocessing Excellence Award from IMAPAC, a leading consulting ... to recognize outstanding leaders and trend-setters of today, ... and biomanufacturing experts in the industry, along with ...
(Date:3/29/2017)... 29, 2017  Halozyme Therapeutics, Inc. (NASDAQ: HALO), ... therapies, today announced that an Oncologic Drug Advisory ... voted 11 to 0 that the benefit/risk of ... favorable for patients in the proposed indications of ... lymphocytic leukemia. The FDA action date is June ...
(Date:3/29/2017)... 2017 Research and Markets has announced the ... - Industry Forecast to 2025" report to their offering. ... The Global Agricultural ... 7.8% over the next decade to reach approximately $825.4 million by ... and forecasts for all the given segments on global as well ...
(Date:3/29/2017)... The Global Microfluidic Chips Market by Manufacturers, Countries, Type ... study on the existing state of the global Microfluidic Chips industry ... and Asia-Pacific , South ... Africa . ... Browse 172 Tables and Figures, 13 Major Company Profiles, spread ...
Breaking Biology Technology: